MIBC Tumor Subtypes May Guide Neoadjuvant Chemotherapy Use
Neoadjuvant chemotherapy response rates differed among patients with genomically unstable bladder tumors, urothelial-like bladder tumors, and basal/squamous subtypes.
Bladder Cancer
BLADDER CANCER ADVISOR
FEATURED CONTENT
-
-
Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer. -
FDA Label Restriction Triggers Increased Uptake of PD-L1 Assays in Urothelial Carcinoma
FDA label changes for certain immunotherapies may have prompted a marked increase in the use of PD-L1 assays. -
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Adding Gemcitabine at the Time of Resection Reduces Recurrence, Cost in Early-Stage Bladder Cancer
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.
BLADDER CANCER NEWS
Local Docetaxel Therapy May Benefit Patients With High-Risk NMIBC
MRI-Based Assessment May Eliminate Need for TURBT in Muscle-Invasive Bladder Cancer
Tislelizumab Shows Promising Antitumor Benefits in Advanced Bladder Cancer
More Advanced Bladder Cancers Encountered After COVID-19 Pandemic
Data Reveal Growing Burden of Metastatic Cancers in the US
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
Loading... 
Loading...